5-Year Outcomes of a Single Institution Prospective Trial of 19 Gy Single-Fraction HDR Brachytherapy for Low- and Intermediate-Risk Prostate Cancer
We previously reported preliminary results of our 19 Gy single-fraction HDR brachytherapy protocol for low/intermediate-risk prostate cancer showing favorable efficacy and toxicity. Here we report that the long-term results have demonstrated a highly favorable toxicity profile, but with a higher than expected rate of local failure. We therefore recommend against treatment with this dose fractionation and hope to see further study of dose escalation with single-fraction regimens.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Zaid A. Siddiqui, Gary S. Gustafson, Hong Ye, Alvaro A. Martinez, Beth Mitchell, Evelyn Sebastian, Amy Limbacher, Daniel J. Krauss Tags: Clinical Investigation Source Type: research
More News: Biology | Brachytherapy | Cancer | Cancer & Oncology | Physics | Prostate Cancer | Radiology | Study | Toxicology